Amylyx Pharmaceuticals, Inc. - AMLX

SEC Filings Our AMLX Tweets

About Gravity Analytica

Recent News

10.29.2026 - LUMINA: AMX0114 ALS Study Update
06.24.2026 - Advancing AMX0114 for ALS: Updates from the LUMINA Phase 1 Study
06.16.2026 - Participant-Informed Design Considerations in Phase 3 LUCIDITY Trial of Avexitide for Post-Bariatric Hypoglycemia
06.16.2026 - Characterizing the Burden of Post-Bariatric Hypoglycemia in the United States
12.08.2025 - A Phase 1, Multicenter, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in Amyotrophic Lateral Sclerosis (LUMINA)
12.08.2025 - Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial
10.09.2025 - Maria and Kelly Story
10.08.2025 - Update on the Phase 2b Portion of the ORION Trial in Progressive Supranuclear Palsy (PSP)
10.07.2025 - Presentation: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS
10.07.2025 - Poster: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS

Recent Filings